DGAP-News: Oasmia Pharmaceutical AB: Björn Björnsson new Chairman of the Board of Oasmia Pharmaceutical AB
(firmenpresse) - DGAP-News: Oasmia Pharmaceutical AB / Key word(s): Change of
Personnel/Change of Personnel
Oasmia Pharmaceutical AB: Björn Björnsson new Chairman of the Board of
Oasmia Pharmaceutical AB
08.02.2011 / 17:59
---------------------------------------------------------------------
Uppsala, Sweden, February 8, 2011. The Board of Directors of Oasmia
Pharmaceutical AB has elected Björn Björnsson as new chairman. At the same
time, Peter Ström has been elected deputy Chairman of the Board.
Following discussions among the major shareholders, the board and
management of Oasmia Pharmaceutical AB and with the aim of securing
continued focus on the important internal and external processes to
register and subsequently launch new products, Mr Bo Cederstrand has
announced that he would like to resign as chairman of the board.
Furthermore, the board and Mr Julian Aleksov have come to an agreement to
initiate a process to jointly find a replacement for him as CEO of the
company. The reason is that the board wishes to prioritize the development
of the large company potential and at the same time restore the confidence
for the company.
The board has for these reasons:
- appointed Mr Björn Björnsson as new Chairman of the Board. Björn
Björnsson is Chairman of the Board of Bure Equity AB and Skrindan AB and
Member of the Board of Oasmia Pharmaceutical AB since 2010. Björn Björnsson
has extensive experience as board member of quoted companies.
- appointed Mr Peter Ström as deputy Chairman of the Board. Peter Ström has
extensive experience from the life science sector from e.g IMS Health, Kabi
Vitrum, Kabi Pharmacia and Pharmacia Upjohn. Peter Ström has an MA in
Economics and is also a board member of Comtax AB, Active Biotech AB, Lidds
AB and Stockholm Corporate Finance AB. Peter Ström is a board member of
Oasmia Pharmaceutical AB since 2006.
Bo Cederstrand and Julian Aleksov, who initiated the project in 1995 (the
company was formed in 1999) and have since then been a driving force and
also to a large extent financed the operations, will remain as Members of
the Board.
With his thorough knowledge of the industry, Peter Ström will be involved
in day-to-day operations to a larger extent and act as additional support
for the management.
Continued focus on registration and product launches
Oasmia Pharmaceutical has the following objectives:
- to achieve market registrations during 2011 in order for the licensees to
launch Paccal(R) Vet, the company's first product for the veterinary
market.
- to submit a market registration application in Europe during 2011 for the
company's first product for the human market, Paclical(R).
The board has noted a few inaccuracies in earlier prospectuses, mainly
concerning the ownership of Oasmia SA. Oasmia SA has separately clarified
the factual circumstances in this matter. The board of directors regret
that the communication has not in all aspects been fully correct, but is of
the opinion that the communication has not misrepresented Oasmia
Pharmaceutical AB and the company's ownership structure.
About Oasmia
Oasmia Pharmaceutical AB develops a new generation of drugs within human
and veterinary oncology. The product development aims to manufacture novel
formulations based on well-established cytostatics which, in comparisonwith current alternatives, show improved properties, a reduced side-effect
profile and an expanded therapeutic area. The product development is based
on in-house research within nanotechnology and company patents. The company
was registered in 1999 and is located in Uppsala, Sweden. Oasmia is
currently listed on NASDAQ OMX Stockholm and Frankfurt Stock Exchange.
For more information, please contact:
Maria Lundén, Head of Public Relations, Oasmia Pharmaceutical AB.
E-mail: press(at)oasmia.com Phone: +46 (0) 18 50 54 40.
German contact : Axel Mühlhaus, edicto GmbH, Frankfurt
E-Mail: oasmia(at)edicto.de Phone: +49 (0) 69 90 55 05 52.
Information is also available at www.oasmia.com www.nasdaqomxnordic.com
www.boerse-frankfurt.de
Disclaimer
This press release includes forward-looking statements that involve a
number of risks and uncertainties, the outcome of which could materially
and/or adversely affect actual future results and the trading price of
Oasmia's securities. Specifically, the risks and uncertainties that could
affect the development of Paccal(R) Vet include risks associated with
preclinical and clinical developments in the biopharmaceutical industry in
general, and with Paccal(R) Vet in particular, including, without
limitation, the potential for Paccal(R) Vet to be proved safe and effective
(or to achieve response rates) for the treatment of the indications noted
in this press release or any other indication, determinations by
regulatory, patent and administrative governmental authorities, the
potential that Paccal(R) Vet will not produce high rates of complete
remission in patients with mastocytoma, the possibility that the
registration trial for Paccal(R) Vet as a treatment for mastocytoma in dogs
will not occur, the possibility that the U.S. Food and Drug Administration
will not approve a phase III registration strategy for Paccal(R) Vet if
proposed by Oasmia, the potential that Abbott will not exercise its
distribution rights, Oasmia's ability to continue to raise capital as
needed to fund its operations, competitive factors, technological
developments, and costs of developing, producing and supplying Paccal(R)
Vet. Except as may be required by law, Oasmia does not intend to update or
alter its forward-looking statements whether as a result of new
information, future events or otherwise.
End of Corporate News
---------------------------------------------------------------------
08.02.2011 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
111520 08.02.2011
Datum: 08.02.2011 - 17:59 Uhr
Sprache: Deutsch
News-ID 33166
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 206 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Oasmia Pharmaceutical AB: Björn Björnsson new Chairman of the Board of Oasmia Pharmaceutical AB"
steht unter der journalistisch-redaktionellen Verantwortung von
Oasmia Pharmaceutical AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
